Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 3/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9606663 | 1.00 | FKBP1A (0.37) | FKBP1ATOP2ADUT | |
| SCHEMBL30106079 | 1.00 | FKBP1A (0.37) | FKBP1ATOP2ADUT | |
| SCHEMBL420544 | 0.90 | FKBP1A (0.36) | FKBP1ATOP2ADUT | |
| SCHEMBL11970804 | 0.86 | TOP2A (0.38) | FKBP1ATOP2ADUT | |
| SCHEMBL19783450 | 0.84 | DUT (0.33) | DUT | |
| SCHEMBL7790340 | 0.78 | DUT (0.35) | DUT | |
| SCHEMBL15570491 | 0.77 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL8972926 | 0.76 | IRAK4 (0.35) | FKBP1ATOP2ADUT | |
| SCHEMBL20660408 | 0.76 | IRAK4 (0.35) | FKBP1ATOP2ADUT | |
| SCHEMBL8062803 | 0.76 | FKBP1A (0.33) | FKBP1ATOP2ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263390-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-21 | — | — | US | disclosed |
| EP-4508030-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023198907-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2023-10-19 | — | — | WO | disclosed |
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2391212-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-8039507-B2 | Therapeutic substituted gamma lactams | ALLERGAN, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010088167-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-7705001-B2 | Therapeutic substituted gamma lactams | ALLERGAN, INC (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090239867-A1 | THERAPEUTIC SUBSTITUTED GAMMA LACTAMS | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20080255220-A1 | For treating inflammatory bowel disease, glaucoma or ocular hypertension, asthma; 7-[(3R*,4R*)-2-Oxo-4-((E)-3-oxo-oct-1-enyl)-pyrrolidin-3-yl]-hept-5-ynoic acid methyl ester; prostaglandin EP2 agonists | ALLERGAN, INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263390-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | GPER1, ESR2, ESRRA | FKBP1A 1679/4885TOP2A 2334/4885DUT 4022/4885 |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | FKBP1A 3582/4885TOP2A 123/4885DUT 264/4885 |
| US-20090239867-A1 | THERAPEUTIC SUBSTITUTED GAMMA LACTAMS | DDO, DAO, GLA | FKBP1A 1517/4885TOP2A 33/4885DUT 453/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | FKBP1A 2736/4885TOP2A 262/4885DUT 2673/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | FKBP1A 2736/4885TOP2A 262/4885DUT 2673/4885 |
| US-20080255220-A1 | For treating inflammatory bowel disease, glaucoma or ocular hypertension, asthma; 7-[(3R*,4R*)-2-Oxo-4-((E)-3-oxo-oct-1-enyl)-pyrrolidin-3-yl]-hept-5-ynoic acid methyl ester; prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER1 | FKBP1A 1366/4885TOP2A 654/4885DUT 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.